The introduction of glucagon-like peptide-1 (GLP-1) receptor agonists, corresponding to semaglutide (Ozempic and Wegovy) is a breakthrough within the administration of weight problems....
A number of healthcare leaders are displaying their assist for the Biden-Harris Administration’s new proposed rule that might broaden protection of GLP-1s for...